ストックスクリーナーアプリを入手
39.39
0.43%
-0.17
Moderna Inc (MRNA) 最新ニュース
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
California’s bird flu emergency spotlights need for advanced therapeutics - Proactive Investors UK
Is Moderna Stock a Buy? - MSN
3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool
Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch
Moderna, Inc. (MRNA) Faces Criticism from Cramer Amid High R&D Spending and Revenue Struggles - Insider Monkey
Personalis Secures $50M from Merck, Extends Collaboration with Moderna - HIT Consultant
RNA Therapy Clinical Trials Market to Reach USD 4.16 Billion to 2034 - BioSpace
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Lands $50M Merck Investment, Extends Key Moderna Partnership for Cancer Therapy Platform - StockTitan
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Stifel Financial Corp - MarketBeat
Moderna Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Moderna lowered to hold at Argus amid lower COVID vaccine sales, competitive RSV market - MSN
Argus downgrades Moderna to hold on weak near-term outlook - MSN
This Feels Like the Post-Pandemic Rally. 3 Stocks to Buy If It Is - 24/7 Wall St.
Moderna shares downgraded to hold from buy by Argus on revenue decline - Investing.com
Argus Downgrades Moderna (NASDAQ:MRNA) to Hold - MarketBeat
Hedge Funds Think That Moderna, Inc. (MRNA) Will Bounce Back Soon - Insider Monkey
Moderna: Cutting Costs Might Not Be Enough (NASDAQ:MRNA) - Seeking Alpha
Moderna Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Moderna Halts mRNA RSV Vaccine Trial for Children After Five Infants were Hospitalized - WCBM
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop - BioSpace
Moderna Inc. stock rises Monday, still underperforms market - MarketWatch
What's Going On With Moderna Stock On Monday? - Yahoo Finance
Moderna remains the most shorted among S&P 500 healthcare stocks in November - MSN
What's Going On With Super Micro Computer Shares Monday? - Benzinga
Some Of This Year’s Big Losers Look Good To Me - Forbes
Moderna Continues To Slide YTD with Stock (MRNA) Down 62% - AskTraders
Is Moderna Stock Underperforming the Dow? - Nasdaq
Is Moderna Stock Underperforming The Dow? - Barchart
Five things: Editas cuts, CVS shares, Moderna's name and the best birthday gift ever - The Business Journals
Adult Vaccines Market Generated Opportunities, Future Scope - openPR
MicroStrategy, Palantir added to Nasdaq 100, with Moderna facing an exit - The Star Online
Cambridge drugmaker wins city approval to put its sign above the treeline - The Business Journals
Quantinno Capital Management LP Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming DeadlinesMRNA - Victoria Advocate
Toronto Dominion Bank Raises Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Saylor’s MicroStrategy Scores Again With Nasdaq 100 Addition - Yahoo Finance
MicroStrategy, Palantir, Axon Added To Nasdaq 100: Super Micro Computer, Moderna, Illumina Exit The Index - Benzinga
MicroStrategy, Palantir Added to Nasdaq 100, Moderna Removed - Bloomberg
Palantir, MicroStrategy Likely To Join Nasdaq 100; Will Moderna, Super Micro Get The Axe? - MSN
Moderna | History, Innovation, Challenges, & Facts - Britannica
‘Safety signal’ in Moderna’s RSV vaccine studies halts trials of other vaccines for childhood killer - Science
FDA panel seeks more data on RSV vaccine safety in infants - BioPharma Dive
Moderna's SWOT analysis: stock faces transition as covid vaccine demand wanes - Investing.com
Is Moderna Stock A Sell In December 2024 With Deep Losses Projected For The Fourth Quarter? - Yahoo! Voices
FDA Committee Calls For More Research After Moderna’s RSV Vaccine Safety Issues - BioSpace
Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Geode Capital Management LLC - MarketBeat
The specter of RFK Jr. has investors fretting about a onetime vaccine wunderkind - Yahoo Canada Finance
Moderna, Inc. (NASDAQ:MRNA) Receives $79.50 Consensus Price Target from Analysts - MarketBeat
Moderna Fires Back With Counterclaims In GSK RSV Vax Suit - Law360
Moderna Inc. stock outperforms competitors despite losses on the day - MarketWatch
January 2025 Options Now Available For Moderna (MRNA) - Nasdaq
MRNA Deadline: MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit - Victoria Advocate
Top 10 Coronavirus Treatment Companies | Best Healthcare SolutionsMarket.us Media - Market.us Media - United States Market News
0.16%
2.65%
大文字化:
|
ボリューム (24 時間):